Experienced biotech executive heads global marketing in the next growth phase of the company
SEATTLE, September 17, 2024–(BUSINESS WIRE)–Parse Biosciencesa leading provider of scalable single-cell sequencing solutions, today announced that Kaitie Kramer has joined the company as Vice President of Marketing. She will be responsible for marketing strategy for the company and its growing portfolio of single-cell solutions, including the Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR and CRISPR Detect platforms.
“As Parse gains market share in the U.S. and abroad, we are recruiting talent to lead us through the next phase of growth,” said Parse CEO and co-founder Alex Rosenberg, PhD. “Kaitie’s extensive experience in this market will be very valuable to Parse, and we are fortunate to have her join our leadership team.”
Kramer has over 20 years of experience in the biotech business. She joins from Twist Bioscience, where she served as Senior Director of Commercial Marketing and led key growth and brand awareness initiatives. She also has extensive expertise in single cells and cell biology. While working for Illumina as the first sales specialist in single cell sequencing, she was part of the team that increased awareness of new applications and developed use cases for single cell sequencing.
Previously, she held senior marketing and business development roles at Thermo Fisher Scientific, Illumina, and Irvine Scientific. She holds a BS in Genetics from the University of Wisconsin-Madison.
Kramer said, “I am excited to join Parse Biosciences as we continue to pioneer single-cell biology. The Parse team is known for delivering innovative, high-quality solutions that make single-cell technologies accessible and affordable to all, and the scalability is unmatched.” Kramer continued, “It is inspiring how our customers are using Parse tools to advance biology. I am honored to be a member of this team and to help shape the future of cell biology together with our wonderful customers.”
Read more
About Parse Biosciences
Parse Biosciences is a global life sciences company dedicated to accelerating progress in human health and scientific discovery. Parse Biosciences enables researchers to sequence single cells at unprecedented scale and with unprecedented efficiency. The company’s pioneering approach has yielded breakthrough discoveries in cancer treatment, tissue regeneration, stem cell therapy, kidney and liver disease, brain development and the immune system.
With technologies developed by co-founders Alex Rosenberg and Charles Roco at the University of Washington, Parse has raised more than $50 billion in capital and is now used by 2,000 customers worldwide. Its growing product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture and a data analytics solution.
Parse Biosciences is based in Seattle’s vibrant South Lake Union neighborhood, where the company recently moved into a new headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
The source language in which the original text is published is the official and authorized version. Translations are provided for ease of understanding. Only the language version that was originally published is legally binding. Therefore, compare translations with the original language version of the publication.
View original version on businesswire.com: https://www.businesswire.com/news/home/20240917638232/de/
Contacts
Jay Roberts, SRPR
jay@shevrushpr.com | 917.696.2142
